Amoy Diagnostics Co., Ltd.

Shenzhen Stock Exchange 300685.SZ

Amoy Diagnostics Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2023: 15.35%

Amoy Diagnostics Co., Ltd. Return on Equity (ROE) is 15.35% for the year ending December 31, 2023, a -12.71% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Amoy Diagnostics Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2022 was 17.59%, a 0.17% change year over year.
Amoy Diagnostics Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2021 was 17.56%, a 9.87% change year over year.
Amoy Diagnostics Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2020 was 15.98%, a 6.40% change year over year.
Amoy Diagnostics Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2019 was 15.02%, a -10.33% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

Shenzhen Stock Exchange: 300685.SZ

Amoy Diagnostics Co., Ltd.

CEO	Ms. Ying Chen
IPO Date	Aug. 3, 2017
Location	China
Headquarters	39 Dingshan Road
Employees	1,119
Sector	Healthcare
Industries Biotechnology

Description

Amoy Diagnostics Co., Ltd., a diagnostic company, focuses on molecular diagnostics for oncology precision medicine in China and internationally. The company offers NGS, real-time PCR, FISH, and extraction assays. Amoy Diagnostics Co., Ltd. was founded in 2008 and is based in Xiamen, China.

Key trends

Past 5 years